212 related articles for article (PubMed ID: 21742840)
21. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
23. Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B.
Li MR; Xi HL; Wang QH; Hou FQ; Huo N; Zhang XX; Li F; Xu XY
PLoS One; 2014; 9(6):e98476. PubMed ID: 24905586
[TBL] [Abstract][Full Text] [Related]
24. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
Singh AK; Sharma MK; Hissar SS; Gupta E; Sarin SK
J Viral Hepat; 2014 Jun; 21(6):439-46. PubMed ID: 24750522
[TBL] [Abstract][Full Text] [Related]
25. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Papatheodoridis GV
Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.
Striki A; Manolakopoulos S; Deutsch M; Kourikou A; Kontos G; Kranidioti H; Hadziyannis E; Papatheodoridis G
Liver Int; 2017 Nov; 37(11):1642-1650. PubMed ID: 28345181
[TBL] [Abstract][Full Text] [Related]
28. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
[TBL] [Abstract][Full Text] [Related]
29. Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.
Hara T; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Viral Hepat; 2014 Nov; 21(11):802-8. PubMed ID: 25274427
[TBL] [Abstract][Full Text] [Related]
30. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir.
Jung YK; Kim JH; Lee YS; Lee HJ; Yoon E; Jung ES; Hong SK; Joo MK; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Clin Gastroenterol; 2010 Oct; 44(9):653-7. PubMed ID: 20216430
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
Kim JM; Choe BH; Chu MA; Cho SM
Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.
Sonneveld MJ; Zoutendijk R; Janssen HL
J Viral Hepat; 2011 Jul; 18(7):449-57. PubMed ID: 21692954
[TBL] [Abstract][Full Text] [Related]
34. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
35. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.
Papatheodoridis G; Triantos C; Hadziyannis E; Zisimopoulos K; Georgiou A; Voulgaris T; Vlachogiannakos I; Nikolopoulou V; Manolakopoulos S
J Viral Hepat; 2015 Dec; 22(12):1079-87. PubMed ID: 26146764
[TBL] [Abstract][Full Text] [Related]
36. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients.
Gao L; Hu Y; Shi X; Li X; Zhang D; Ren H
Ann Hepatol; 2020; 19(3):329-334. PubMed ID: 31884016
[TBL] [Abstract][Full Text] [Related]
37. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A
Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368
[TBL] [Abstract][Full Text] [Related]
38. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy.
Zhang XX; Li MR; Xi HL; Cao Y; Zhang RW; Zhang Y; Xu XY
Chin Med J (Engl); 2016 Apr; 129(8):929-35. PubMed ID: 27064037
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.
Hadziyannis E; Hadziyannis SJ
Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):185-95. PubMed ID: 24417264
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis.
Fung J; Wong DK; Seto WK; Kopaniszen M; Lai CL; Yuen MF
Am J Gastroenterol; 2014 Nov; 109(11):1764-70. PubMed ID: 25244963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]